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Autophagy is a conserved catabolic pathway that involves the engulfment of cytoplasmic components such as large protein
aggregates and organelles that are delivered to the lysosome for degradation. This process is important in maintaining neuronal
function and raises the possibility of a role for autophagy in neurodegenerative diseases. Alzheimer’s disease (AD) is the most
prevalent form of these diseases and is characterized by the accumulation of amyloid plaques in the brain which arise due to the
misfolding and aggregation of toxic peptides, including amyloid beta (A𝛽).There is substantial evidence from both ADpatients and
animal models that autophagy is dysregulated in this disease. However, it remains to be determined whether this is protective or
pathogenic as there is evidence that autophagy can act to promote the degradation as well as function in the generation of toxic A𝛽
peptides. Understanding the molecular details of the extensive crosstalk that occurs between the autophagic and endolysosomal
cellular pathways is essential for identifying the molecular details of amyloid toxicity. Drosophila models that express the toxic
proteins that aggregate in AD have been generated and have been shown to recapitulate hallmarks of the disease. Here we focus on
what is known about the role of autophagy in amyloid toxicity in AD frommammalian models and how Drosophilamodels can be
used to further investigate AD pathogenesis.
1. Introduction
Alzheimer’s disease (AD) is the most prevalent form of
neurodegenerative disease characterized by deficiency in
memory and cognitive functions.Thepredominant patholog-
ical changes of AD are the development of amyloid beta (A𝛽)
plaque deposits in specific brain areas andneurofibrillary tan-
gles (NFTs) within neuronal cells, leading to the progressive
loss of synapses, neuronal death, and cognitive decline [1–3].
The extracellular A𝛽 plaques are derived from cleavage of the
amyloid precursor protein (APP). The NFTs consist of intra-
cellular aggregates of the hyperphosphorylated microtubule-
associated protein tau, mutant forms of which are also found
in other neurodegenerative diseases termed tauopathies.This
review will focus on the role of APP and the products arising
from its proteolysis (which includes A𝛽42) in AD.
While the primary mechanisms responsible for AD
pathology remain to be established, there is increasing evi-
dence for a role of the autophagy pathway in AD. Macroau-
tophagy (referred to here as autophagy) is a conserved
catabolic pathway that sequesters cytoplasmic material in a
double-membrane vesicle (of nonlysosomal/vacuolar origin),
the autophagosome, for delivery to the lysosome. Autophagy
is induced in response to cellular stress and protects cells
by eliminating dysfunctional organelles and toxic protein
aggregates. Aberrant regulation of autophagy has significant
adverse consequences to normal cellular functions and is
associated with numerous human pathologies, including
neurodegenerative diseases [4]. This review will describe
the pathogenesis of AD, the conservation of components
of the autophagy machinery, and their known roles in
neurodegeneration. We will discuss evidence of autophagy
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Figure 1: Proteolytic processing of amyloid precursor protein. In the
nonamyloidogenic pathway, transmembrane APP is cleaved by 𝛼-
secretase followed by 𝛾-secretase generating a nontoxic P3 fragment
and 𝛼 C-terminal fragments (𝛼-CTFs), thus preventing the genera-
tion of toxic A𝛽. Alternatively, the amyloidogenic pathway involves
sequential cleavages of APP by 𝛽-secretase followed by 𝛾-secretase
complex, thus generating toxic A𝛽 peptides in addition to the 𝛽-
CTFs and amyloid precursor protein intracellular domain (AICD).
The accumulation of A𝛽 peptides promotes oligomerisation and
formation of insoluble plaques.
perturbation in AD and focus on Drosophila as an ideal
model for understanding the molecular mechanisms by
which autophagy contributes to AD.
2. The Genetics of Alzheimer’s Disease (AD)
There are two types of AD based on genetic inheritance and
age of onset. Familial AD is rare, affecting approximately
1–5% of individuals that are under 65 years of age. Auto-
somal dominant mutations have been identified in amyloid
precursor protein (APP) as well as presenilin-1 (PS1) and
presenilin-2 (PS2) genes that encode the catalytic subunit of 𝛾-
secretase complex that cleavesAPP to promote the generation
of A𝛽 peptides as causative agents for familial AD [13, 14].
Sporadic, late-onset AD accounts for more than 95% of
cases with both genetic and environmental factors contribut-
ing to the pathogenesis. While the genetic contribution in
these patients is not fully defined, genome-wide association
studies have identified several loci associated with increased
AD risk in genes involved in various biological pathways
including cholesterol/sterol metabolism (APOE-𝜀4), innate
immunity (CR1, CD33, and TREM2), and endolysosomal
and autophagy pathways (BIN1, PICALM, and CD2AP) [15,
16]. In addition, recent studies in mammalian cells further
support the role of abnormal trafficking in the endolysosomal
and autophagy pathways contributing to AD [17, 18].
3. Proteolysis of Amyloid Precursor Protein
APP is a transmembrane protein that undergoes sequential
cleavage by one of two pathways (Figure 1). The initial pro-
teolytic cleavage of APP by either 𝛼-secretase (nonamyloido-
genic processing) or 𝛽-secretase (amyloidogenic processing)
produces APP-carboxy-terminal fragments (CTFs) as well as
secreted APP peptides. In the nonamyloidogenic pathway, 𝛼-
secretase (ADAM10) cleavage occurs within the A𝛽 region
generating 𝛼-carboxy-terminal fragments (𝛼-CTFs) and thus
prevents the formation of toxic A𝛽 [19, 20]. The 𝛼-CTF is
further cleaved by 𝛾-secretase complex to release P3 peptide
as well as an APP intracellular domain (AICD) [21]. In
the amyloidogenic pathway, APP is initially cleaved by 𝛽-
secretase 1 (beta-site amyloid precursor protein cleaving
enzyme 1, BACE1) to produce 𝛽-carboxy-terminal fragments
(𝛽-CTFs). Subsequent cleavage of 𝛽-CTF by 𝛾-secretase
complex releases toxic amyloid-𝛽 (A𝛽) peptides (Figure 1).
While the processing of APP by 𝛼-secretase is predominantly
localized to the cell surface, amyloidogenic cleavage occurs in
endosomes, lysosomes, and autophagic vacuoles [22–24].
The amyloidogenic processing of APP increases the gen-
eration of A𝛽 that is susceptible to aggregation with other A𝛽
peptides accumulating into fibrils. This is commonly found
in amyloid plaques in the brain (where A𝛽42 aggregates are
considered to be toxic) and is one of the hallmarks of AD. In
addition to A𝛽 toxicity, the 𝛽-CTFs may also contribute to
the pathogenesis of AD through multiple pathways [25, 26].
The AICDs of both cleavage pathways can translocate to
the nucleus and induce nuclear signalling [27–29]. However,
the principle physiological functions of APP remain largely
undetermined. The proposed role for APP acting as a cell
surface receptor or as a ligand, such as transcriptional
regulation and/or synaptic functioning, requires further in
vivo characterization [30]. While the generation of extra-
cellular A𝛽 plaques is central to the hypothesis of amyloid
as the causative agent in AD [31], additional factors have
been identified which may contribute to the onset and/or
progression of AD with dysregulation of autophagy thought
to be an early event. Despite advances in the understanding of
AD pathogenesis, further studies are required to understand
themolecular mechanism by which autophagy contributes to
disease pathogenesis. In addition, the consequence of A𝛽 as
well as other products from APP processing on other cellular
processes including autophagy needs further investigation.
4. Autophagy Molecular Machinery
Autophagy is a highly conserved catabolic pathway that
degrades/recycles cytoplasmic material such as large protein
aggregates and organelles. The cytoplasmic components are
engulfed by a double-membrane vesicle, the autophagosome,
for delivery to the lysosomes for degradation (Figure 2).
Autophagy has essential functions in normal development,
cell growth, metabolism, cell death, infection, and immunity
[32–34]. It also acts to protect cells by eliminating toxic
protein aggregates, unwanted cellular contents, dysfunc-
tional organelles, and invading pathogens. Under growth-
promoting conditions, low basal rates of autophagy are
required to maintain cellular homeostasis. In response to
extracellular and intracellular stresses, such as nutrient limi-
tation, intracellular metabolic stress, organelle damage, and
infection, high levels of autophagy are induced to recycle
cytoplasmic material to maintain vital cellular processes [35].
The tightly coordinated multistep process of autophagy is
regulated by a number of distinct autophagy-related (ATG)
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Figure 2: Schematic representation of the autophagy pathway and the regulatory machinery. The multiple steps of autophagy can be divided
into initiation, nucleation, expansion, vesicle completion, and lysosome fusion. Several ATG proteins form distinct complexes that function
in different stages of autophagy.TheULK1/ATG1 complex (consisting of ULK1, ATG13, ATG17, andATG101) is responsible for the initiation of
autophagy.The class III phosphatidylinositol 3-kinase (PI3K) complex (BECN1, VPS34, VPS15, andATG14), ATG9, andATG2-WIPI complex
nucleate and assemble the membrane to form the double-membrane phagophore. The LC3 and ATG12 conjugation systems can be involved
the formation of the autophagosome. Once completed, the autophagosome fuses with the lysosome where the enclosed components are
degraded by lysosomal enzymes.
gene products that assemble into specific complexes [36].
Many of these components are evolutionarily conserved from
yeast to mammals, including in Drosophila (Table 1). The
autophagy process/complexes can be functionally divided
into (i) initiation, (ii) autophagosome nucleation, (iii) expan-
sion and vesicle completion, and (iv) lysosome fusion [37–40]
(Figure 2).
4.1. Initiation and Nucleation. Autophagy is initiated by
the formation of a double-membrane structure called the
phagophore (also called the isolation membrane) that fur-
ther expands to encapsulate part of the cytoplasm into the
autophagosome [41]. A key early step in autophagy induction
requires the activity of the ULK1 (Atg1 in Drosophila) kinase
complex, comprisingULK1/Atg1, ATG13, FIP200/ATG17, and
ATG101. The activity of this complex is regulated in response
to stress signals [42]. Nucleation from the phagophore
(isolation membrane) requires active ULK1 kinase com-
plexes for the recruitment of class III phosphatidylinositol
3-kinase (PI3K) complex. This complex consists of VPS34,
VPS15, ATG14, and Beclin 1 (Atg6 in Drosophila) to generate
phosphatidylinositol 3-phosphate (PI3P) required for vesicle
nucleation.
4.2. Expansion and Vesicle Completion. The expansion
and completion to form the autophagosome requires two
ubiquitin-like conjugation systems: the Atg8/LC3-lipid phos-
phatidylethanolamine (PE) and the ATG12-ATG5 systems
[37, 43, 44]. There are six Atg8 family members in mammals,
including LC3A, LC3B, LC3C, and GABARAP proteins [45]
and two in Drosophila with Atg8a shown to be essential for
autophagy [46]. Prior to lipidation, LC3/Atg8 is cleaved to
produce a C-terminal glycine residue (LC3-I form) by the
cysteine protease, ATG4.This enables the conjugation of LC3
to PEmediated by ATG7 (E1-like enzyme) andATG3 (E2-like
enzyme). In the ATG12-ATG5 conjugation system, ATG7 and
ATG10 (E1- and E2-like enzymes, respectively) mediate the
conjugation ofATG12 toATG5,which associateswithATG16.
To enable phagophore expansion a supply of lipid bilayers
is required and is thought to involve the transmembrane
protein ATG9; however its exact function remains unclear.
Membrane closure is thought to involve ATG2, in combina-
tionwithWIPI1/Atg18, to regulate autophagosome formation
[47].
4.3. Lysosomal Fusion. The final step in autophagy is fusion
of the autophagosomewith the lysosome to form an autolyso-
some [37]. Lysosomes are specialized organelles that function
to break down extracellular materials and recycle cellular
components from the secretory, endocytic, autophagic, and
phagocytic pathways [48]. The lysosome contains hydrolytic
enzymes required for degradation, including cathepsin pro-
teases that are activated by the acidic pH within the lyso-
some generated by proton-pumping vacuolar H+ ATPase (v-
ATPase) [49]. The fusion between autophagosome and lyso-
some requires the soluble N-ethylmaleimide-sensitive factor
activating protein receptor (SNARE) complex consisting of
syntaxin 17 (STX17) and synaptosomal-associated protein
29 (SNAP29). This complex forms on autophagosomes to
promote tethering with vesicle-associated membrane pro-
tein 8 (VAMP8) on lysosomes, resulting in fusion to form
autolysosomes [50].
4.4. Amphisome Formation. Instead of fusing with a lyso-
some, an autophagosome can also fuse with a late endo-
some/multivesicular body to form an amphisome [51].
Amphisomes contain markers of both autophagosomes (lip-
idated LC3) and endosomes (RAB5, RAB7, and RAB11) [52,
53]. Members of the endosomal sorting complex required for
transport (ESCRT) complex are required during endocytosis
as well as for later endosomal maturation and amphisome
formation during autophagy [54].
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Table 1: Conserved Autophagy-related genes in Drosophila, neurodegenerative phenotypes, and/or modification of AD models.
Human gene Drosophila gene Neurodegenerativephenotype in Drosophila Modification of AD model in Drosophila
Initiation
ULK1/ATG1 Atg1 Decreased lifespan andclimbing defect [6]
Deficiency line with decreased Atg1

















Conjugation systems ATG5 Atg5 Climbing defect [7] Decreased Atg5 reduced A𝛽42accumulation [8]
Conjugation systems ATG7 Atg7 Decreased lifespan andclimbing defect [9]
Conjugation systems
MAP1LC3A





Conjugation systems ATG10 Atg10
Conjugation systems ATG12 Atg12 Decreased Atg12 reduced A𝛽42accumulation [8]
Conjugation systems ATG16L1 Atg16 Decreased lifespan andclimbing defect [11]
ATG9 trafficking system ATG9A Atg9
ATG9B





Deficiency line with decreased Atg18a





4.5. Selective Autophagy. The targeting of cytoplasmic mate-
rial to the autophagosome can also occur in a specific man-
ner, by recognizing selective substrates. These can include,
for example, damaged mitochondria (mitophagy), excess
peroxisomes (pexophagy), and aggregate-prone proteins,
including those causing many neurodegenerative conditions
(aggrephagy) [38]. The selection of autophagic cargo can be
determined by cargo receptors that interact with LC3 family
member proteins on the membrane [55]. The multifunc-
tional scaffold protein SQSTM1/p62 (known as Ref(2)P in
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Drosophila) binds ubiquitinated proteins and acts as a cargo
receptor by binding LC3/Atg8 targeting ubiquitinated pro-
teins for degradation by autophagy [56].The type of ubiquitin
linkages on the substrate can lead to different functional
outcomes. The most common ubiquitin linkage tags proteins
for degradation of the ubiquitin-proteasome system, whereas
other linkages can direct nonproteasomal fates. There are
a growing number of identified cargo receptors that bind
specific substrates that are taggedwith ubiquitin chains.Thus,
the receptors serve as a link between ubiquitinated cargo and
the autophagy pathway to enable the selective incorporation
of the cargo into autophagosomes.
5. Role for Autophagy in Maintaining
Neuronal Homeostasis
Multiple upstream signalling pathways regulate autophagy
induction with nutrient deprivation, one of the most well
characterized signals. The target of rapamycin (TOR) kinase
is a central mediator in regulating the response to nutri-
ents and growth signalling and forms a multisubunit com-
plex, mTORC1 [57]. In the presence of growth signals,
mTORC1 is activated, thus preventing autophagy by inhibit-
ing ULK1/Atg1 kinase. Under growth-limiting conditions,
mTORC1 is no longer active in enabling autophagy induction
by activation of ULK1/Atg1 [58, 59]. Numerous studies link
alterations of mTOR pathway to age-dependent cognitive
decline and to pathogenesis of Alzheimer disease (AD) [60],
highlighting the importance of maintaining physiological
levels of autophagy to promote neuronal health.
Several nervous system-specific conditional knockout
mouse models of autophagy pathway genes have highlighted
the importance of autophagy inmaintaining the normal func-
tions and homeostasis of the nervous system.The conditional
deletion of Atg5 and Atg7 in neuronal precursor cells results
in autophagy deficiency, accompanied by the accumulation
of intraneuronal aggregates in neurons resulting in neuronal
loss and neurodegeneration [61–63]. The accumulation of
these aggregates in otherwise normal mice suggests that
autophagy plays a key role in removing aggregate-prone pro-
teins.Othermousemodels of autophagy deficiency, including
conditional knockout for FIP200 andWipi4, as well asUlk1/2
double knockout [64–66], similarly show reduced survival
and early-onset, progressive neurodegeneration across broad
areas of the brain. However, each model presents variations
in the pathology observed which may be due to the specific
stage of autophagy that is disrupted, as well as any potential
autophagy independent gene functions.
Reduced function of conserved autophagy genes in
Drosophila also results in neurodegenerative phenotypes
(Table 1). Initiation of autophagy requires Atg17/Fip200, and
reduced expression in adult flies resulted in a climbing defect
as well as decreased survival [6]. Atg5 null flies displayed
mobility defects [7], and decreasedAtg16 resulted in climbing
defects and decreased survival [11]. Atg7 mutants show a
shortened lifespan as well as accumulation of aggregated
ubiquitin-positive lesions in neuronal cells [9] while Atg8a
mutants that are viable show decreased lifespan [10]. Taken
together, these studies demonstrate the critical and conserved
role of autophagy in neuronal homeostasis with the impaired
clearance by autophagy likely to be a key factor in the
accumulation of toxic peptides in the neurons.
6. Autophagy in Alzheimer’s Disease
A hallmark of AD and other neurodegenerative diseases is
the accumulation of large protein aggregates/inclusions and
defective organelles. Autophagy is an essential degradation
pathway involved in the clearance of abnormal protein
aggregates as well as maintaining protein homeostasis in
neuronal cells [67]. There is substantial evidence from both
AD patients as well as animal models for the dysregulation
of autophagy in this disease. Current findings suggest that
impairment of the autophagy pathway leads to defects in
the clearance of protein aggregates which is likely to occur
early in the pathogenic process, before plaque formation or
NFTs deposition [68–70]. However the role of autophagy
in AD (in particular which stage is affected) and its alter-
ation during disease progression in neurons is complex
and remains largely unclear. Alterations to autophagy have
also been identified in other neurodegenerative diseases,
including Parkinson’s disease and Huntington’s disease [71].
There is also evidence for mitophagy in these diseases;
however, that is outside the focus of this review and has been
reviewed elsewhere [72]. In healthy neurons, autophagy is
constitutively active and highly efficient, with low levels of
autophagosomes detected [73]. Early observations revealed
the accumulation of abnormal subcellular vesicles in the
dystrophic or swollen neurites in AD patient brains [74].
Further evidence for disruption to autophagy flux in AD
was revealed by the identification of autophagosomes and
other immature autophagic vesicles that accumulated in
dystrophic neurites in AD brains [68]. While clinical data
has identified defects in autophagosomal biogenesis, whether
this is pathogenic or a consequence of earlier defects is still
controversial. Also, there is evidence that autophagy may not
only act to promote the degradation of A𝛽 but may also be
involved in its generation [8, 75].
To aid in understanding the role of autophagy in AD, ani-
malmodels have provided a tool for in vivo studies. A number
of transgenic mouse models have been generated based on
the genetic pathways disrupted in AD [76]. In an APP/PS1
transgenic mouse model that contains human transgenes for
APP and PS1, both of which are carrying human disease
mutations, neuronal autophagy is detected in the brain
before the appearance of A𝛽 plaques [22]. Consequently,
autophagosomes and late autophagic vacuoles/intracellular
trafficking vesicles accumulate in dystrophic dendrites, sug-
gesting impaired maturation of autophagosomes to lyso-
somes [22]. Similarly, in another study young (4- to 6-
month-old) APP/PS1 mice accumulated abnormal immature
autophagosomes in axons of hippocampus neurons before
neuronal loss [77]. The localization of both APP and PS1
to autophagic vacuoles suggests that A𝛽 may be generated
during autophagy [22, 78]. This indicates that accumula-
tion of autophagic vacuoles/intracellular trafficking vesicles
may be a source of A𝛽 production contributing to AD
progression.
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Altering the level of autophagy has also been examined
in AD models. APP transgenic mice with Atg7 deletion
showed a reduction in A𝛽 extracellular secretion and plaque
formation [79, 80]. This block in A𝛽 secretion resulted in an
accumulation of intracellular A𝛽 and enhanced neurodegen-
eration was observed. An increase in the level of autophagy
by rapamycin inhibition of mTOR in APP transgenic mice
reduced A𝛽 levels and prevented AD-like cognitive deficits
[81]. These findings suggest that autophagy may function
in either degradation or secretion in A𝛽 and supports a
role for autophagy in limiting the accumulation of toxic
A𝛽.
There is further evidence from animal models that basal
autophagy is beneficial for decreasing the pathology in AD.
In the APP mouse model of AD, heterozygous deletion
of BECN1 decreases neuronal autophagy and increases the
accumulation of both intraneuronal and extracellular A𝛽
deposits followed by neurodegeneration [82]. In support of
this, reduced levels of Beclin 1/BECN1 have been detected
in the brains of patients with severe AD [82]. Consistent
with this, a mouse knockin of a Beclin 1 gain of function
mutation resulted in constitutively active autophagy and,
when combined with an AD mouse model, showed reduced
A𝛽 accumulation, prevented cognitive decline, and restored
survival [83]. This suggests that in AD, BECN1 induced
autophagy contributes to reduction in levels of A𝛽 pep-
tides/aggregates. In an alternative approach, aged (7-month-
old) APP/PS1 transgenic mice were transfected with miR-
124 lentiviral vector that downregulates BACE1 [84]. These
mice also showed increased Beclin 1 with alleviation of AD
pathology but surprisingly they had decreased expression of
other autophagy markers. This suggests that Beclin 1 may
not be acting via the autophagic pathway in this system and
may have other roles such as in the PtdIns 3-kinase complex
(Rubicon-UVRAG-Beclin 1-hVps34-hVps15) that localizes to
the late endosome/lysosome and inhibits autophagy [85].
Together these data highlight the need for comprehensive in
vivo analyses to dissect the role of individual autophagy genes
in AD pathogenesis.
7. Crosstalk between Autophagy and
the Endolysosomal System in AD
The subcellular distribution of APP plays a key role in A𝛽
production and occurs within the autophagy and endolyso-
somal systems [86, 87]. The early endosome is the site of
colocalization of APP and BACE1 promoting the proteolytic
cleavage of APP [88, 89]. Indeed, endosomal pathology is
one of the earliest defects observed in AD [90, 91]. Altered
levels of the endosomal small GTPase, Rab5, precede A𝛽
deposition [91], and A𝛽 colocalizes in Rab5 endosomes in
neurons from AD brain [23]. More recently, expression of a
dominant negative Rab5 mutant was shown to reduce APP-
induced axonal blockages in both cultured neurons and an
in vivo Drosophila model [92]. Genome-wide association
studies identified mutations in endosomal genes including
BIN1,CD2AP, and PICALM, which supports the involvement
of the endosomal network in processing and trafficking of
APP proteolytic fragments [15]. Drosophila homologues of
these genes show interactions with increased tau expression
[17, 93, 94] but they have not been tested with respect to
amyloid pathology.
Themetabolism of APP in endolysosomal and autophagy
networks is consistent with crosstalk between these pathways.
Autophagic and lysosomal genes are coordinately regulated
by a complex transcriptional program mediated by Tran-
scription Factor EB (TFEB) [95]. TFEB levels have been
found to be decreased in brains of Alzheimer’s patients [96]
while an increase in TFEB expression has been shown to
be protective for A𝛽-induced pathogenesis [97]. Similarly,
in an APP/PS1 mouse model, the overexpression of TFEB
increases lysosome biogenesis and reduces A𝛽 levels [98]. In
Drosophila there is a single TFEB orthologue, Mitf, which
has been shown to have a role in regulation of the v-ATPase
proton pump as well as other components of the lysosomal-
autophagic pathway to promote clearance of protein aggre-
gates [99, 100].
As both endocytic and autophagic pathways lead to
the lysosome, it is not surprising that aberrant lysosomal
function contributes to AD pathogenesis. Defective lysoso-
mal membrane integrity has been detected in AD patients
suggesting dysfunction [101]. Increased expression levels of
lysosomal proteases in the early phase of AD patients have
also been reported [102]; it is likely that this increased
lysosomal function is in response to increased pathogenic
load. The AD-associated risk factor gene Apolipoprotein E4
(ApoE4) also affects lysosomal function. Transgenic mice
that overexpress ApoE4 accumulate A𝛽42 in lysosomes and
there is death of neurons in the hippocampus [103]. Also
in Neuro-2a cells, ApoE4 can affect lysosomal membrane
permeabilization causing the release of proteolytic enzymes
that can mediate cell death [104]. Further support for the
function of lysosomes in AD was highlighted by the role of
PS1 in the assembly of the v-ATPase pump in the lysosomal
membrane, thus promoting acidification and contributing
to autophagy degradation in a 𝛾-secretase-independent way
[105]. An alternative report suggested that the lysosome
dysfunction resulting from loss of PS1 could be attributed
to alterations in lysosomal calcium storage [106]. Increased
or sustained activation of Glycogen synthase kinase-3 also
affects lysosome acidification and has been shown to affect
the autophagic degradation of APP [107, 108]. In addition,
consideration needs to be given to the physiology of neuronal
cells where retrograde transport of distally located autophagic
vacuoles (mostly amphisomes) is required before any fusion
can occur with lysosomes that are located in the soma
[109].
These findings and others, including cell culture stud-
ies not described here, clearly establish autophagic and
endolysosomal dysfunction in AD. Using model organ-
isms to gain an understanding of the exact contribution
of these pathways to the pathogenesis of AD will be a
priority to enable the development of specific therapeu-
tic interventions that do not affect other essential cellular
processes.
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Table 2: The human genes that function in APP proteolysis and their Drosophila orthologues.
Human gene Drosophila gene Functions
Amyloid precursor protein
(APP) Appl
APP is an integral membrane protein containing an A𝛽-like region that is cleaved
by BACE1.
Amyloid precursor-like
proteins (APLP1 and APLP2)
Sequence divergence at the internal A𝛽 site of APLP1 and APLP2 prevents cleavage
by BACE1. The principal functions of APLP1 and APLP2 remain unknown.
Presenilin 1 Presenilin
The catalytic subunit of the 𝛾-secretase enzyme complex, also required for
lysosomal acidification.
Presenilin 2 Component of 𝛾-secretase complex.
ADAM 10 Kuzbanian A neuronal 𝛼-secretase that cleaves APP at the plasma membrane vianonamyloidogenic processing.
BACE1 Bace
𝛽-secretase enzyme activity cleaves APP in early endosome and promotes
amyloidogenic processing with A𝛽 production.
BACE2 𝛽-secretase related to BACE1 that is thought to contribute to Alzheimer’s disease.
8. Advantages of Using Drosophila to
Model Amyloid Pathology
More than 77% of human disease genes listed on the OMIM
database have an orthologue in Drosophila, confirming their
utility as a model for human genetic diseases [110]. In
addition, it is possible to avoid complications that could
arise from redundancy as there is often a single gene in
Drosophila compared with multiple genes in mammalian
systems as is the case for APP (Table 2). Knockdown
and ectopic expression constructs are readily available in
Drosophila for most genes and the genetic toolkit available
for analyses is constantly being developed and refined [111].
Ectopic expression via the GAL4/UAS system is used most
frequently where various tissue-specific “drivers” (i.e., gene-
specific promoter regions upstreamof aGAL4 transcriptional
activation domain) give particular patterns of expression.
Driver lines most useful for studies of molecular mechanisms
of AD include the endogenous APPL promoter (appl-GAL4),
the eye driver (gmr-GAL4), the neuronal driver (elav-GAL4),
and ones that express specifically in cholinergic neurons (cha-
gal4), glial cells (repo-GAL4), or ubiquitously (da-GAL4
or actin5C-GAL4) (Figure 3(a)) [12]. Inducible expression
systems are also available (e.g., GeneSwitch) which allow
for studies where the timing of transgene expression can be
regulated more precisely [112].
Ectopic expression of human sequences encoding full
length APP (with or without BACE1) or A𝛽1–42 peptides
(wild-type or mutant) in transgenes under UAS control gives
rise to neuronal dysfunction which can be measured as
retinal degeneration, locomotor defects, decreased longevity,
learning and memory defects, and alterations to various
cell biological markers [113] (Figure 3). These have been
used as the basis for genetic and/or pharmacological screen-
ing [114–117]. Other novel approaches to ameliorating AD
symptoms inDrosophilamodels include immunotherapy and
photodynamics [118, 119]. In addition, the contribution of
nonneuronal cell types to AD disease progression is well
established. Glial cells have been shown to clear neuro-
toxic A𝛽 peptides in the adult Drosophila brain through
a Draper/STAT92E/JNK cascade that may be coupled to
protein clearance pathways such as autophagy [120]. The
genetic systems available in Drosophila also allow for elegant
approaches for understanding the complex interactions that
occur between neurons and glia that could contribute to AD
[121].
9. Drosophila Models for Amyloid Toxicity
Components of APP proteolysis are conserved in Drosophila
(see Table 2). Although there is limited sequence conser-
vation across the A𝛽42 region, it has been shown that
neuronal dBACE like enzyme activity can lead to cleavage
of the APP-like (APPL) protein in Drosophila where the
resultant peptide gives rise to neurodegenerative phenotypes
that are accompanied by A𝛽-like deposits [122]. Processing
of APPL gives rise to the same types of cleavage fragments
shown for humanAPP in Figure 1 including small membrane
bound intracellular CTFs and neurotoxic A𝛽-like peptides,
and these have been shown to be expressed throughout
the nervous system during development [123]. Given that
APPL is conserved throughout evolution suggests that it
does have important functions, some of which have been
uncovered including its role in neuronal outgrowth and
synapse formation, regulation of the circadian clock, and
providing neuroprotection in models for AD as well as other
neurodegenerative diseases [123–125].
Despite the conservation of endogenous APP processing
and function in Drosophila, disease models have predomi-
nantly been generated based on ectopic expression of human
counterparts based on the mutations identified in genetic
pathways involved in AD (Table 2) (Figure 3). Various
model systems have been developed whereby the human
gene products are ectopically expressed in Drosophila.Many
studies have determined the effects of expressing the A𝛽42
toxic peptide directly and it has been shown to give rise to age-
dependent neurodegenerative phenotypes that are accompa-
nied by significant disruption to the correct functioning of
the autophagic-lysosomal system [126]. It was shown that
A𝛽42 carrying the “Arctic” APP human disease mutation
(E22G) has more severe effects as it is thought to increase
the rate of A𝛽42 aggregation [127, 128]. However these
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Figure 3: Drosophila models of AD and assays for neurodegeneration. (a) Drosophilamodels of AD. The GAL4/UAS system is routinely used
in Drosophila to drive expression of a gene of interest [12]. There are ubiquitous or tissue-specific enhancers that drive expression of GAL4.
By crossing lines containing the driver-GAL4 to the UAS-gene of interest, the progeny will result in ectopic expression. Eye, neuronal, glial,
or ubiquitous drivers are used to express A𝛽 or APP and BACE1 transgenes resulting in specific phenotypes. These can be assessed for neural
degeneration and dysfunction. (b) Assays to assess neuronal dysfunction. Using the eye-specific driver GMR-GAL4, APP + BACE1 can be
expressed during eye development and the adult eye disruption can be observed. The degenerative eye shows disruption of ommatidial
structure, reduced size, and loss of pigmentation. This is a useful system to screen for modifiers of APP + BACE1 toxicity. Lifespan analyses
can be performed using neuronal, glial, or ubiquitous cell type driver lines and the effect of genetic modifiers on the longevity of APP +
BACE1 flies can also be monitored. Climbing assays can be used to examine locomotor deficits that are known to degenerate with age. Flies
are tapped to the bottom of a measuring cylinder and the number of flies that can climb above a certain height is recorded. Also relevant for
studies in AD are assays for learning and memory such as odour preference teamed with an electrical shock treatment.
A𝛽42 expression constructs require the inclusion of signal
sequences from unrelated genes to ensure their secretion and
it has been shown that, at least in some cases, these can
give alternative effects [129]. Nonetheless, A𝛽42 is localized
within endosomes and has been proposed to be the cellular
source of pathogenicA𝛽42 [8].Thepresence ofA𝛽40was also
observed but found not to correlate with toxicity. Similarly
comparison of A𝛽40 with A𝛽42 by others has also shown
differential effects in memory testing [130]. In addition
ectopic expression of A𝛽43 was tested separately and found
to be neurotoxic, potentially by acting to prime the formation
of amyloid aggregates [131].
Ectopic expression of the full length (695 amino acid)
APP is also used in Drosophila models for AD where again
both wild-type and disease associated mutations have been
investigated. Wild-type human APP expressed in combi-
nation with ectopic human BACE1 enzyme gives effective
processing of APP and leads to neuropathology [132]. Synap-
tic abnormalities have also been reported when APP and
BACE1 are coexpressed specifically in neuronal cells [133].
Interestingly, it has been shown that equivalent amounts of
A𝛽42 peptide produced from processing of APP (when it is
expressed together with BACE1) give stronger effects in vivo
than A𝛽42 peptide expressed directly as the secreted form
[134].This suggests that incorporating the findings fromAPP
and BACE1 ectopic expression models will contribute sig-
nificantly to the understanding of the molecular pathogenic
mechanisms of the proteolytic products of APP.
10. Role for Autophagy in Drosophila
Models for AD
Similar to mammalian systems there is accumulating evi-
dence for a role of autophagy in the pathogenesis of
Drosophila models for AD. Amyloid toxicity models tested
to date have concentrated on those ectopically expressing the
A𝛽42 peptide (Table 2). Increased basal autophagy by various
methods in these models suppresses ectopic A𝛽42 induced
phenotypes [135, 136]. Specific components of the autophagy
pathway have also been investigated by genetic modification
analyses in these A𝛽42 models. Decreased expression of
Atg1 or Atg18 was found to enhance the neurotoxic effect in
flies expressing A𝛽42, also supporting a protective role for
autophagy [5]. However, contrary to this, the knockdown of
Atg5 or Atg12 was shown to decrease accumulation of A𝛽42
[8]. These findings suggest that there is a complex role for
components of the autophagic pathway in AD which may
be attributed to the particular stage of the process and/or
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correlate with timing of disease progression. Together they
highlight the need for a comprehensive genetic dissection of
the autophagy pathway to determine its contribution to AD.
11. Ageing, Autophagy, and AD
Age is the most prominent risk factor in the development
of AD. Age-related dysfunction of autophagy may play
a causative role in the onset and progression of AD. It
has been suggested that the neuronal autophagy-lysosomal
system may shift from a functional and protective state to a
pathological and deleterious state either during brain ageing
or via A𝛽42 neurotoxicity [137]. In support of this there is
also an age-related decline in clearance of A𝛽42 via the X-
box protein 1 [138]. An aged onset model has been developed
in Drosophila where human APP and human BACE1 are
expressed at low levels during development followed by
increased expression throughout adulthood [139]. This type
of model will enable in vivo studies in Drosophila to more
closely represent disease progression as it occurs in humans.
Drosophila is also an excellent model to dissect the molecular
mechanisms of ageing that are relevant for AD related
neuronal dysfunction [140].
12. Conclusions and Future Directions
The contribution of autophagy to AD has been controversial.
In particular, it remains to be determined whether autophagy
plays a causative or a protective role in AD or whether
autophagy defects are a consequence of disease progression.
The detection of aberrant autophagy alone is not sufficient
to support a causative role, and further detailed molecular
analysis is required. However, there is clear evidence to sug-
gest that autophagy is involved in AD pathophysiology. With
therapeutic intervention based on modulating autophagy, it
will be critical to understand the role of autophagy in the
different stages of the disease as well as defining themolecular
mechanisms underlying autophagy dysfunction inAD.While
the strongest evidence for the contribution of dysfunctional
autophagy to AD comes from in vivo studies, in vitro cell
studies have contributed to the understanding of autophagy
defects in AD.
Disruption to autophagy could occur at different steps
in the pathway from initiation, elongation, cargo selection,
lysosomal fusion, and degradation.This may result in altered
autophagic flux, with accumulation of autophagosomes,
autolysosomes and/or amphisomes, and lysosomal defects
that may present as different pathological outcomes. In addi-
tion, there is a tissue-specific requirement for distinct com-
ponents of the autophagic machinery as well as autophagy
independent functions of a number of Atg genes [46, 141].
Given the controversy as to the protective and/or pathogenic
role of autophagy in AD, using Drosophila models to dissect
out the contribution of the different steps will provide
important information about the origin of dysfunctional
autophagic processes in AD.
Alzheimer’s disease pathology is remarkably complex
and human genetic mutations have highlighted alterations
to amyloid processing as a primary event that gives rise to
neuronal toxicity. Autophagy as part of a cellular clearance
mechanism has been shown to play a prominent role in
disease progression but its functional contribution to neuro-
toxicity and/or neuroprotection has not been fully defined.
In addition some clues have emerged as to the role of
nonneuronal cells, in particular glial cells and their interac-
tions with neuronal cells that can affect neuronal function.
Using the genetic platform provided by Drosophila, these
pathways can be fully dissected and cellular mechanisms
of neuronal dysfunction identified. This could include a
multigenic approach where more than one candidate can
be tested for their effects on APP processing and disease
progression. In addition, given that ageing is the most
prominent risk factor in AD, the time-frame that would
be required for determining efficacies of drugs in humans
is not feasible. With the development of technology that
can detect amyloid in the blood as an early biomarker for
Alzheimer’s disease [142, 143], this now provides the oppor-
tunity for early intervention and there is a pressing need for
identifying new therapeutic compounds. By understanding
the role of autophagy in progression/prognosis, this will
provide potential novel ways to treat AD and/or provide
prognostic biomarkers of disease. Again Drosophila presents
as an ideal system where specific autophagic mechanisms
could be targeted for the development of novel therapies for
early intervention in AD.
Conflicts of Interest
The authors declare no conflicts of interest regarding the
publication of this paper.
Acknowledgments
The research involving autophagy in DD laboratory was
supported by the National Health and Medical Research
Council of Australia Project Grant (1124490).
References
[1] D.M.Holtzman, J. C.Morris, andA.M.Goate, “Alzheimer’s dis-
ease: the challenge of the second century,” Science Translational
Medicine, vol. 3, no. 77, Article ID 77sr1, 2011.
[2] Y. Huang and L.Mucke, “Alzheimer mechanisms and therapeu-
tic strategies,” Cell, vol. 148, no. 6, pp. 1204–1222, 2012.
[3] M. Ingelsson, H. Fukumoto, K. L. Newell et al., “Early A𝛽
accumulation and progressive synaptic loss, gliosis, and tangle
formation in AD brain,” Neurology, vol. 62, no. 6, pp. 925–931,
2004.
[4] B. Levine and G. Kroemer, “Autophagy in the pathogenesis of
disease,” Cell, vol. 132, no. 1, pp. 27–42, 2008.
[5] Y. Omata et al., “Age-induced reduction of autophagy-related
gene expression is associated with onset of Alzheimer’s disease,”
American Journal of Neurodegenerative Disease, vol. 3, no. 3, pp.
134–142, 2014.
[6] M. Kim, H. L. Park, H.-W. Park et al., “Drosophila Fip200 is an
essential regulator of autophagy that attenuates both growth and
aging,” Autophagy, vol. 9, no. 8, pp. 1201–1213, 2013.
10 BioMed Research International
[7] M. Kim, E. Sandford, D. Gatica et al., “Mutation in ATG5
reduces autophagy and leads to ataxia with developmental
delay,” eLife, vol. 5, 2016.
[8] D. Ling, M. Magallanes, and P. M. Salvaterra, “Accumula-
tion of amyloid-like A𝛽1-42 in AEL (autophagy-endosomal-
lysosomal) vesicles: potential implications for plaque biogene-
sis,” ASN Neuro, vol. 6, no. 2, pp. 95–109, 2014.
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